Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LETROZOLE

All products: general benefit

Other products in the same Health Canada class (L02B, L02BG) — coverage varies; not interchangeable

  • Anastrozole (Arimidex): general benefit
  • Exemestane (Aromasin): general benefit
  • Abiraterone (Zytiga): general benefit
  • Bicalutamide (Casodex): general benefit, Not a benefit
  • Degarelix (Firmagon): general benefit
  • Flutamide (Euflex): general benefit, Not a benefit

3 more in the class list below

Apo-Letrozole · DIN 02358514 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Letrozole · DIN 02358514 Manufacturer: Apotex Inc.; listing date 2011-05-19 Health Canada: Marketed since 2020-11-24 · brand APO-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84356 · Verify on the e-Formulary ↗ (DIN 02358514)

Source record
DIN 02358514: Apo-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id APX Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02358514 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84356
Interchangeable products
CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2024-11-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02358514
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Femara · DIN 02231384 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Femara · DIN 02231384 Manufacturer: Novartis Pharma Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 1997-09-02 · brand FEMARA · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50695 · Verify on the e-Formulary ↗ (DIN 02231384)

Source record
DIN 02231384: Femara Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id NOV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $8.9293; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231384 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50695
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231384
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Letrozole Tablets · DIN 02541912 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Letrozole Tablets · DIN 02541912 Manufacturer: Jamp Pharma Corporation; listing date 2024-10-31 Health Canada: Marketed since 2024-08-20 · brand JAMP LETROZOLE TABLETS · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Letrozole Tablets: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103052 · Verify on the e-Formulary ↗ (DIN 02541912)

Source record
DIN 02541912: Jamp Letrozole Tablets Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541912 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103052
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2026-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541912
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Letrozole · DIN 02504472 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Letrozole · DIN 02504472 Manufacturer: Sanis Health Inc.; listing date 2021-05-31 Health Canada: Marketed since 2026-02-25 · brand LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99389 · Verify on the e-Formulary ↗ (DIN 02504472)

Source record
DIN 02504472: Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id SAI Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02504472 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99389
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2026-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02504472
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Letrozole · DIN 02524244 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Letrozole · DIN 02524244 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-09-29 Health Canada: Marketed since 2022-07-18 · brand LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101329 · Verify on the e-Formulary ↗ (DIN 02524244)

Source record
DIN 02524244: Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id SIV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524244 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101329
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: active shortage (reported 2024-08-15, last updated 2024-11-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524244
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Letrozole Tablets USP · DIN 02338459 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Letrozole Tablets USP · DIN 02338459 Manufacturer: Accord Healthcare Inc.; listing date 2010-07-20 Health Canada: Marketed since 2014-05-03 · brand ACH-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Letrozole Tablets USP: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82411 · Verify on the e-Formulary ↗ (DIN 02338459)

Source record
DIN 02338459: Letrozole Tablets USP Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id ACH Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02338459 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82411
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2025-12-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02338459
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Letrozole · DIN 02373424 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Letrozole · DIN 02373424 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-01-19 Health Canada: Marketed since 2022-02-09 · brand MAR-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85857 · Verify on the e-Formulary ↗ (DIN 02373424)

Source record
DIN 02373424: Mar-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id MAR Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02373424 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85857
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2019-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02373424
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Letrozole · DIN 02508109 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Letrozole · DIN 02508109 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2021-10-29 Health Canada: Marketed since 2026-05-05 · brand MINT-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99746 · Verify on the e-Formulary ↗ (DIN 02508109)

Source record
DIN 02508109: Mint-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id MIN Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508109 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99746
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2026-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508109
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Letrozole · DIN 02520486 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Letrozole · DIN 02520486 Manufacturer: Nora Pharma; listing date 2022-06-30 Health Canada: Marketed since 2022-03-25 · brand NRA-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100968 · Verify on the e-Formulary ↗ (DIN 02520486)

Source record
DIN 02520486: NRA-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id NRA Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02520486 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100968
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02520486
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nat-Letrozole · DIN 02421585 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Nat-Letrozole · DIN 02421585 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2015-04-30 Health Canada: Marketed since 2015-02-03 · brand NAT-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Natco pharma (canada) inc · schedule Prescription
Check this DIN again · Health Canada product record

Nat-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90623 · Verify on the e-Formulary ↗ (DIN 02421585)

Source record
DIN 02421585: Nat-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id NAT Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02421585 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90623
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421585
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Letrozole · DIN 02309114 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Letrozole · DIN 02309114 Manufacturer: Pharmascience Inc.; listing date 2010-07-20 Health Canada: Marketed since 2010-04-28 · brand PMS-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79471 · Verify on the e-Formulary ↗ (DIN 02309114)

Source record
DIN 02309114: PMS-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id PMS Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02309114 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79471
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2024-02-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02309114
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Letrozole · DIN 02398656 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Riva-Letrozole · DIN 02398656 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Marketed since 2024-07-03 · brand RIVA-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Riva-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88359 · Verify on the e-Formulary ↗ (DIN 02398656)

Source record
DIN 02398656: Riva-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id RIA Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02398656 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88359
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2025-03-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02398656
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Letrozole · DIN 02344815 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Letrozole · DIN 02344815 Manufacturer: Sandoz Canada Inc.; listing date 2010-06-14 Health Canada: Marketed since 2010-04-27 · brand SANDOZ LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83029 · Verify on the e-Formulary ↗ (DIN 02344815)

Source record
DIN 02344815: Sandoz Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id SDZ Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02344815 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83029
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2026-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02344815
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Letrozole · DIN 02343657 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Letrozole · DIN 02343657 Manufacturer: Teva Canada Limited; listing date 2013-06-27 Health Canada: Marketed since 2013-07-08 · brand TEVA-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82909 · Verify on the e-Formulary ↗ (DIN 02343657)

Source record
DIN 02343657: Teva-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id TEV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02343657 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82909
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended 2025-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02343657
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Letrozole · DIN 02373009 · 2.5mg · tablet

General benefitDormant since 2026-08-03 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Letrozole · DIN 02373009 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Health Canada: Dormant since 2026-08-03 · brand JAMP-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85813 · Verify on the e-Formulary ↗ (DIN 02373009)

Source record
DIN 02373009: Jamp-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02373009 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85813
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02373009
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.

Med-Letrozole · DIN 02322315 · 2.5mg · tablet

General benefitDormant since 2018-05-25 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Med-Letrozole · DIN 02322315 Manufacturer: Generic Medical Partners Inc.; listing date 2010-07-20 Health Canada: Dormant since 2018-05-25 · brand MED-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Generic medical partners inc · schedule Prescription
Check this DIN again · Health Canada product record

Med-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80777 · Verify on the e-Formulary ↗ (DIN 02322315)

Source record
DIN 02322315: Med-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id GMP Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02322315 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80777
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02322315
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2018-05-25 — choose a marketed DIN from the same-category list.

Zinda-Letrozole · DIN 02378213 · 2.5mg · tablet

General benefitDormant since 2018-07-17 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Zinda-Letrozole · DIN 02378213 Manufacturer: Stason Pharmaceuticals Inc., Irvine; listing date 2014-01-03 Health Canada: Dormant since 2018-07-17 · brand ZINDA-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Stason pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Zinda-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86404 · Verify on the e-Formulary ↗ (DIN 02378213)

Source record
DIN 02378213: Zinda-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id STA Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02378213 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86404
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378213
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2018-07-17 — choose a marketed DIN from the same-category list.

CCP-Letrozole · DIN 02459884 · 2.5mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.Discontinued 2023-08-03 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
CCP-Letrozole · DIN 02459884 Manufacturer: CellChem Pharmaceuticals Inc.; listing date 2018-01-31 Health Canada: Cancelled post market since 2023-08-03 · brand CCP-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Cellchem pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

CCP-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94719 · Verify on the e-Formulary ↗ (DIN 02459884)

Source record
DIN 02459884: CCP-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id CCP Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02459884 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94719
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02459884
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.

Letrozole · DIN 02348969 · 2.5mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-18 — choose a marketed DIN from the same-category list.Discontinued 2018-06-18 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-18 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-06-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Letrozole · DIN 02348969 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2010-07-20 Health Canada: Cancelled post market since 2018-06-18 · brand LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Actavis pharma company · schedule Prescription
Check this DIN again · Health Canada product record

Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83427 · Verify on the e-Formulary ↗ (DIN 02348969)

Source record
DIN 02348969: Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id COB Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02348969 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83427
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02348969
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-06-18 — choose a marketed DIN from the same-category list.

Ran-Letrozole · DIN 02372282 · 2.5mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-11-22 — choose a marketed DIN from the same-category list.Discontinued 2022-11-22 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-11-22 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-11-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Letrozole · DIN 02372282 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-12-15 Health Canada: Cancelled post market since 2022-11-22 · brand TARO-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Letrozole: Formulary list price $1.3780/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85742 · Verify on the e-Formulary ↗ (DIN 02372282)

Source record
DIN 02372282: Ran-Letrozole Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id RAN Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.3780; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372282 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85742
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Femara · DIN 02231384 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02372282
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-11-22 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FEMARA® (letrozole) film-coated tablets is indicated for: • The adjuvant treatment of postmenopausal women with hormone receptor-positive invasive early breast cancer. Clinical effectiveness is based on superior Disease-Free Survival (DFS) compared to tamoxifen. Overall survival was not significantly different between the two treatments (see 14 CLINICAL TRIALS). • The extended adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy. Clinical effectiveness is based on superior Disease-Free Survival (DFS) compared to placebo in the overall study population, at a median follow-up of 28 months. However, overall survival was not significantly different between the two treatments for the overall population and an increase in deaths was seen in node-negative patients in the FEMARA arm versus the placebo arm (see 7 WARNINGS AND PRECAUTIONS and 14 CLINICAL TRIALS). • First-line therapy in postmenopausal women with advanced breast cancer. • … https://pdf.hres.ca/dpd_pm/00071188.PDF PM date: May 16, 1997 Source product: FEMARA; DIN 02231384; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Letrozole · DIN 02524244 Shortage status: active shortage (reported 2024-08-15, last updated 2024-11-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524244

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)